Ivacaftor hydrate VX-770 hydrate
产品编号:Bellancom-13017B| CAS NO:1134822-07-3| 分子式:C24H30N2O4| 分子量:410.51
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
Ivacaftor hydrate VX-770 hydrate
产品介绍 | Ivacaftor hydrate (VX-770 hydrate) 是一种可口服的 CFTR 增强剂,可用于囊性纤维化的研究。 |
---|---|
生物活性 | Ivacaftor hydrate (VX-770 hydrate) is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment. |
体外研究 |
Ivacaftor (10 µM) increases the PC secretion activity by 3-fold for ABCB4-G535D, 13.7-fold for ABCB4-G536R, 6.7-fold for ABCB4-S1076C, 9.4-fold for ABCB4-S1176L, and 5.7-fold for ABCB4-G1178S. Ivacaftor corrects the functional defect of ABCB4 mutants. Ivacaftor (10 μM) significantly increases CFTR activity in W1282X-expressing cells compared to R1162X CFTR cells. Ivacaftor shows no significant activity against 160 targets tested including the GABAA benzodiazepine receptor. Ivacaftor increases the chloride secretion with an EC50 of 0.236 ± 0.200 μM, a 10-fold shift in potency compared to the F508del HBEs. In recombinant cells, VX-770 increases CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation. VX-770 increases forskolin-stimulated IT in temperature-corrected F508del-FRT cells by appr 6-fold with an EC50 of 25 nM[4]. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. |
体内研究 |
Ivacaftor (1-200 mg/kg, p.o.) exhibits good oral bioavailability in rat. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. |
体内研究 |
Ivacaftor (1-200 mg/kg, p.o.) exhibits good oral bioavailability in rat. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. |
性状 | |
溶解性数据 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
参考文献 |
|